Non-selective NSAIDs, but not cyclooxygenase-2 (COX-2) inhibitors, were associated with an increased risk of treatment-resistant depression among outpatients with multimorbidity and major depression. The gene discussed is PTGS2; the disease is depressive symptom measurement.